• Ongoing phase 2 trial with up to 150 patients
  • RRMM patients with few or no remaining treatment options
  • Patients have received ?2 earlier lines of therapy with IMiDs and PIs and are refractory to pomalidomide and/or daratumumab
  • Supports OCEAN for marketing authorization
  • Potential for FDA accelerated approval if data is exceptionally strong
  • Started in Q1 2017, data reporting in 2018/2019 and follow-up 2019/2020